


An Introduction to Diabetes


Dr Ketan Dhatariya MBBS MSc MD MS FRCP
Consultant in Diabetes and Endocrinology
Norfolk and Norwich University Hospitals

Why is This an Important Subject?




Because the presence of any form of retinopathy is associated with an increased all-cause mortality rate

Causes of Blindness in England and Wales 1999-2000




Bunce C et al Eye 2008;22:905-911

Number of People with Blindness Due to DR in 1990 and 2010



Number of People with MSVI Due to DR in 1990 and 2010



Leasher JL et al. Diabetes Care 2016;39(9):1643-1649

What is Diabetes Mellitus?

A complex metabolic disorder characterised by chronic hyperglycaemia resulting from defects in insulin secretion or insulin action, or both

First described in 1550 BC

Two Main Types

- Type 1
 - Autoimmune destruction of the β cells of the Islets of Langerhans in the pancreas. This leads to an absolute insulin deficiency. Insulin treatment is therefore mandatory
 - Previously known as IDDM or juvenile onset diabetes

Two Main Types

- Type 2
 - Impaired insulin action (insulin resistance) and eventually, impaired insulin secretion as well
 - Usually treated with oral medication initially, then may move onto insulin
 - Formerly known as NIDDM or maturity onset diabetes

Other Types

- Gestational diabetes
- Drug induced diabetes
- Genetic disorders
- Pancreatic disease

How is the Diagnosis Made?

Test	Value
HbA1c	>48mmol/mol (6.5%)
Fasting glucose	>7.0mmol/l (126mg/dl)
2-hour glucose after a 75g oral glucose load	>11.1mmo/l (200mg/dl)
Random glucose	>11.1mmol/l (200mg/dl)

So, in summary, making the diagnosis of diabetes is not as straightforward as it used to be

Familial Risks

	Type 1	Type 2
If neither parent has it	1 in 250	10%
If mother has it	1 in 50 - 100	20 – 30 %
If father has it	1 in 12	20 – 30 %
If 1 sibling has it	1 in 15 – 30	40%
If 1 sibling and 1 parent has it	1 in 10	
If both parents have it	1 in 3	70%
If an identical sibling has it		80 – 100%

Epidemiology

- The 2008/9 National Diabetes Audit found the prevalence of diabetes to be 4.13% in England and Wales. This rose to 6.6% in 2012 (a 59% increase in 4 years!)
- ~90% of whom have Type 2 diabetes
- Lifetime risk of developing diabetes is about 10%

The Global Burden


WHO Region	Prevalence (%)		Number (millions)		Percentage increase
	1980	2014	1980	2014	
Africa	3.1%	7.1%	4	25	229%
Americas	5%	8.3%	18	62	166%
Eastern Mediterranean	5.9%	13.7%	6	43	232%
Europe	5.3%	7.3%	33	64	137%
SE Asia	4.1%	8.6%	17	96	210%
Western Pacific	4.4%	8.4%	29	131	191%
Total	4.7%	8.5%	108	422	194%

WHO 2016: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1

The Global Burden


 Diabetes related healthcare costs account for about 10% of all health expenditure in developed nations

Relative Risk of Developing Diabetes



- Lower with more lifestyle factors
 - Moderate physical activity
 - Healthy diet
 - Never smoked
 - Moderate alcohol use
 - BMI<25 Kg/m²
 - Waist circumference less than 88 cm for women or 92 cm for men

BMI and Diabetes




Clinical Features

	Type 1	Type 2
Age at Onset (years)	< 40	> 40
Duration of Symptoms	Days or Weeks	Years
Body Weight	Normal or Low	Normal or High
Ketones	Yes	No
Insulin Mandatory?	Yes	No
Autoantibodies	Yes	No
Complications at Diagnosis	No	Up to 20%
Family History?	No	Yes
Other Autoimmune Diseases?	Yes	No
Percentage of cases	10%	90%

Why is it Important?

- Poorly controlled diabetes leads to accelerated cardiovascular morbidity and mortality
- A combination of microvascular and macrovascular disease

 Diabetic retinopathy – the commonest cause of blindness in the developed world



Diabetes and Eyes: Some History

- In the 1970's and 1980's diabetes was the leading cause of severe visual impairment
- People with diabetes were 25 times more likely to have a VA of 20/200 in their best eye due to
 - Haemorrhage
 - Tractional detachment of the macula due to proliferative diabetic retinopathy
 - Macular oedema
 - Cataract
 - Glaucoma


Some History

- There was no definitive evidence that achieving good glycaemic control would actually result in less diabetic retinopathy
- Also, technology was not of a standard to allow easy optimisation of control
- In the early 1970's the efficacy of photocoagulation had not yet been demonstrated
- Vitrectomy was in its developmental stages

WESDR

 It was the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) cohort data that first demonstrated a relationship between glycaemic control and the risk of retinopathy

Retinopathy and Glycaemic Control




The Effects Last for a LONG Time

A Any Diabetes-Related Ocular Surgery

0-

5





10

15


25

30

20


The Effects Last for a LONG Time

B Cataract-Extraction Surgery




The Effects Last for a LONG Time

C Vitrectomy, Retinal-Detachment Surgery, or Both




Epidemiology of Retinopathy



Cross sectional data from 44,623 individuals


Glycaemic Control is Important



Taking The Right Medication

- Taking glucose lowering medication is important
- So are the other medications
 - Such as ACE inhibitors (drugs that end in 'pril' e.g. ramipril, enalapril, lisinopril)
 - Or ARB's (drugs that end in 'artan' e.g. losartan, candesartan, valsartan)
 - Lipid lowering agents

Neuropathy



Combinations of neuropathy and ischaemia








- Nephropathy
 - Diabetes is the commonest cause of End Stage Renal Disease in the developed world


Stroke

Myocardial infarction


Data From 3.3M Danes




Vascular Complications Of Type 2 Diabetes At The Time Of Diagnosis



Lessons from UKPDS: Better Control Means Fewer Complications



Diabetes Related Mortality is Falling




Non-Insulin Hypoglycaemic Agents

- α glucosidase inhibitors
- Metaglinides
- Metformin
- Sulphonylureas
- Thiazolidindiones
- GLP 1 analogues
- DPP IV inhibitors
- SGLT 2 inhibitors

Insulin Durations

Figure 1. Insulin Activity Profiles

Insulin	Onset, min	Duration, h
Very rapid Lispro, aspart, glulisine	10	4
Rapid (regular) CZI	30	4-8
Intermediate NPH	120	8-10
Long acting Glargine, levemir	120	12-24



Insulin Regimens

Breakfast

Lunch

Figure 2. Three Examples of Insulin Regimens for Type 1 Diabetes 3 Daily injections ▲ Injection ▲ Very rapid + Intermediate ▲ Intermediate ▲ Very rapid 4 Daily injections ▲ Very rapid ▲ Very rapid ▲ Very rapid ▲ Long acting Insulin pump regimen Basal insulin pump infusion Very rapid Very rapid Very rapid 10 10 Mid-6 AM 6 AM Noon 2 **6 PM** 8


Dinner

Nathan DM JAMA 2015;314(10):1052-1062

Bedtime

night

Insulin Regimens



In Summary

- Diabetes is very common, and type 2 diabetes is becoming commoner
- Good glycaemic control is important to help reduce the risk of developing the microvascular and macrovascular complications – or to reduce the risk of progression
- Regular screening for complications is essential

What Can YOU Do?

- Ask them if they take all their medication every day
- Ask them to stop smoking
- Ask them to see their doctor if they have any concerns or problems sooner rather than later



An Introduction to Diabetes

www.norfolkdiabetes.com

ketan.dhatariya@nnuh.nhs.uk



